Want to see JAZZ full AI Analyst Report?
JAZZ Stock Chart & Stats
$260.23
$0.36(0.14%)
At close: 4:00 PM EDT
$260.23
$0.36(0.14%)
Day’s Range― - ―
52-Week Range$123.88 - $266.38
Previous CloseN/A
Volume197.25K
Average Volume (3M)988.12K
Market Cap
$15.82B
Enterprise Value$18.93K
Total Cash (Recent Filing)$2.20B
Total Debt (Recent Filing)$4.41B
Price to Earnings (P/E)16.2
Beta0.73
Next Earnings
Nov 11, 2026EPS Estimate
6.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)15.20
Shares Outstanding64,914,570
10 Day Avg. Volume1,347,284
30 Day Avg. Volume988,121
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)2.40
Price to Sales (P/S)2.43
P/FCF Ratio9.05
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$292.19Price Target Upside12.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
EPS Forecast (FY)25.02
Revenue Forecast (FY)$4.72B
Bulls Say, Bears Say
Bulls Say
Revenue Growth And GuidanceBroad-based growth across oncology, rare sleep and established brands supports a durable expansion trend. The raised full-year outlook indicates management sees commercial momentum continuing beyond a single quarter.
Cash Generation And Balance SheetStrong operating cash flow and substantial liquidity improve Jazz’s ability to fund clinical development, acquisitions and debt obligations. Reduced leverage also increases financial flexibility if operating conditions become less favorable.
Oncology Platform ExpansionThe first-line approval expands Ziihera’s addressable patient population and strengthens Jazz’s oncology presence. Its survival data and multiple approved regimens provide a foundation for broader commercial adoption and future indication expansion.
Bears Say
Historical Earnings VolatilityThe recent profitability recovery is encouraging, but repeated loss years show that earnings remain sensitive to product mix, impairments and development spending. This history reduces confidence that current margins will persist through the cycle.
Margin And Cost PressureHigher royalties on oncology products and increased commercial and clinical investment can limit operating leverage. Sustained spending may be strategically necessary, but it creates a continuing risk that revenue growth will not translate proportionally into profit.
Franchise And Competitive RiskPotential generic and novel-mechanism competition could pressure the established oxybate franchise, while the Zepzelca label change may accelerate erosion in its second-line business. These risks could weaken the durability of key revenue streams.
Jazz Pharmaceuticals News
JAZZ FAQ
What was Jazz Pharmaceuticals’s price range in the past 12 months?
Jazz Pharmaceuticals lowest stock price was $123.88 and its highest was $266.38 in the past 12 months.
What is Jazz Pharmaceuticals’s market cap?
Jazz Pharmaceuticals’s market cap is $15.82B.
When is Jazz Pharmaceuticals’s upcoming earnings report date?
Jazz Pharmaceuticals’s upcoming earnings report date is Nov 11, 2026 which is in 69 days.
How were Jazz Pharmaceuticals’s earnings last quarter?
Jazz Pharmaceuticals released its earnings results on Aug 03, 2026. The company reported $5.71 earnings per share for the quarter, missing the consensus estimate of $6.175 by -$0.465.
Is Jazz Pharmaceuticals overvalued?
According to Wall Street analysts Jazz Pharmaceuticals’s price is currently Undervalued.
Does Jazz Pharmaceuticals pay dividends?
Jazz Pharmaceuticals does not currently pay dividends.
What is Jazz Pharmaceuticals’s EPS estimate?
Jazz Pharmaceuticals’s EPS estimate is 6.46.
How many shares outstanding does Jazz Pharmaceuticals have?
Jazz Pharmaceuticals has 64,914,570 shares outstanding.
What happened to Jazz Pharmaceuticals’s price movement after its last earnings report?
Jazz Pharmaceuticals reported an EPS of $5.71 in its last earnings report, missing expectations of $6.175. Following the earnings report the stock price went up 3.991%.
Which hedge fund is a major shareholder of Jazz Pharmaceuticals?
Currently, no hedge funds are holding shares in JAZZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jazz Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$292.19 (12.28% Upside)
$292.19 (12.28% Upside)
Blogger Sentiment
Bullish
JAZZ Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 228.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 1.0%
Last 30 Days ▲ 1.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
89.39%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.25%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Jazz Pharmaceuticals
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
JAZZ Company Deck
JAZZ Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple strong commercial and pipeline wins — record revenue, raised guidance, double-digit growth across key brands (oncology +32%, Xywav +13%, Epidiolex +16%, Zepzelca +42%) and a solid balance sheet — while acknowledging manageable margin pressure from royalties, rising SG&A/R&D investments, label adjustments for Zepzelca second-line, and potential future competitive/generic risks for the oxybate franchise. On balance, the positive execution, guidance raise, cash generation and late-stage regulatory momentum outweigh the identified challenges.View all JAZZ earnings summariesJAZZ Stock 12 Month Forecast
Average Price Target
$292.19
▲(12.28% Upside)
Technical Analysis
Corcept Therapeutics
―
Halozyme
―
Bio-Techne
―
Revolution Medicines
―
Roivant Sciences
―
Ownership Overview
3.34% Insiders
29.46% Mutual Funds
22.76% Other Institutional Investors
19.75% Public Companies and
Individual Investors